NCT06295965 Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
| NCT ID | NCT06295965 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Washington |
| Condition | Recurrent Fallopian Tube Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2024-01-02 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2024-01-02 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.
Eligibility Criteria
Inclusion Criteria: * Subjects who have or have had ovarian, peritoneal, or fallopian tube carcinoma who have a life expectancy of greater than 6 months and: * Have completed or plan to complete at least 5 cycles of platinum-based chemotherapy OR * Subjects who have or have had a solid tumor diagnosis and any of the following: * At least 4 months of exposure to a PARP inhibitor * Diagnosis of a blood disorder including, but not limited to, clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or therapy-related myeloid neoplasm Exclusion Criteria: * Individuals with a life expectancy of less than 6 months
Contact & Investigator
Elizabeth Swisher
PRINCIPAL INVESTIGATOR
Fred Hutch/University of Washington Cancer Consortium
Frequently Asked Questions
Who can join the NCT06295965 clinical trial?
This trial is open to participants of all sexes, studying Recurrent Fallopian Tube Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06295965 currently recruiting?
Yes, NCT06295965 is actively recruiting participants. Contact the research team at swisherlabrc@uw.edu for enrollment information.
Where is the NCT06295965 trial being conducted?
This trial is being conducted at Seattle, United States.
Who is sponsoring the NCT06295965 clinical trial?
NCT06295965 is sponsored by University of Washington. The principal investigator is Elizabeth Swisher at Fred Hutch/University of Washington Cancer Consortium. The trial plans to enroll 2,000 participants.